Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM).
Douglas B. Johnson(Vanderbilt University Medical Center), Adil Daud(University of California, San Francisco), Jeff Hall, Svetlana B. McKee(University of Alabama at Birmingham), David L. Rimm(Yale University), Bashar Dabbas(Lineage Cell Therapeutics (United States)), Richard W. Joseph(Daiichi Sankyo (United States)), John S. Witte(University of California, San Francisco), Nicole Dominiak(Medical University of South Carolina), Thai H. Ho(Mayo Clinic in Arizona), James W. Smithy(Memorial Sloan Kettering Cancer Center), Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Robert M. Conry(University of Alabama), Anastasios Dimou(Mayo Clinic), Christine Vaupel(Navidea Biopharmaceuticals (United States)), Justin M. Balko(Vanderbilt University Medical Center), Ju‐Young Kim(Lineage Cell Therapeutics (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Elizabeth Gaughan(University of Virginia)
Cited by 2
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k